HHS & Healthcare Contracts Intelligence — September 10, 2026

Leidos Biomedical Research secured a $79.9M cost-plus-fixed-fee delivery order from NIH/NCI for the Center for Serological Sciences Network (SeroNet), with total outlays already exceeding the base value at $82.7M and $147.4M in subawards, indicating program scope expansion. The full-and-open competition win signals Leidos' competitive positioning in health R&D services.

BIOQUAL, INC. won a $65.5M cost-plus-fixed-fee contract from NIH/NIAID for animal care and lab support at the Vaccine Research Center, with potential total value of $110.3M including options. The multi-year engagement through 2027 provides stable revenue visibility for this private contractor.

Fisher Bioservices Inc. secured a $62.98M cost-plus-fixed-fee contract from NIH/NIAID for clinical research product development, with $44.1M already outlaid indicating strong execution. The full-and-open competition win demonstrates competitive strength in health R&D services.

The Johns Hopkins University Applied Physics Laboratory LLC received a $49.2M cost-plus-fixed-fee contract from HHS/BARDA to develop RITCA, a disaster response mobile application. The non-competed award signals strong government trust and entrenched relationship, though the nonprofit status limits direct shareholder value.

The Charles Stark Draper Laboratory, Inc. secured a $45.9M cost-plus-fixed-fee contract from BARDA to develop a medical countermeasure evaluation platform using organ-on-chip models, with potential total value of $70.1M. The full-and-open competition win validates Draper's R&D capabilities in biodefense.

ADVANCED TECHNOLOGY INTERNATIONAL's $1.01B contract (77% of total digest value) lacks pricing type, competition signal, and competitive moat data, creating significant opacity around profitability and contract durability. Investors cannot assess whether this is a high-margin sole-source or a low-margin competitive win.

All six contracts are civilian HHS awards, making them vulnerable to discretionary budget cuts or Continuing Resolution (CR) uncertainty, particularly the $1.01B ADVANCED TECHNOLOGY INTERNATIONAL contract awarded in September 2023, which could face funding delays if CRs persist.

Leidos Biomedical Research's $79.9M SeroNet contract has total outlays exceeding the base value at $82.7M, indicating potential cost overruns or scope creep. While cost-plus pricing mitigates downside, execution risk remains if program scope expands beyond budgeted levels.

JHU/APL's $49.2M non-competed BARDA contract could face GAO protests from competitors, potentially delaying program execution or forcing re-competition. The sole-source justification may be challenged if competitors argue they could provide equivalent services.

Leidos Holdings' $79.9M SeroNet win positions the company for follow-on contracts in serological research and pandemic preparedness, given the $147.4M in subawards indicating program expansion. The 2026 contract end date creates a near-term re-compete catalyst.

BIOQUAL's $65.5M NIH vaccine research contract has options that could increase total value to $110.3M, providing upside if the government exercises all options. The contract runs through 2027, offering multi-year revenue visibility.

Draper Laboratory's $45.9M BARDA organ-on-chip contract has potential total value of $70.1M, with options that could expand the program. Success could lead to follow-on contracts as BARDA invests in next-generation biodefense platforms.

Fisher Bioservices' $62.98M NIH clinical research contract has $18.8M remaining under current funding, with potential for option exercises that could increase total value to $85.3M. The contract runs through June 2027, providing a re-compete catalyst.

Three of six contracts ($208.4M combined) were awarded by NIH/NIAID for serological research, vaccine development, and clinical research, indicating sustained investment in pandemic preparedness infrastructure despite the post-COVID environment.

Two contracts totaling $95.1M were awarded by HHS/BARDA for disaster response mobile applications and organ-on-chip medical countermeasure platforms, signaling increased investment in next-generation biodefense technologies.

All five contracts with disclosed pricing types are cost-plus-fixed-fee, indicating the government is bearing cost risk in health R&D programs. This reduces downside for contractors but caps margin upside, making these contracts more about revenue stability than profit growth.

{"entity" => "Leidos Holdings, Inc.", "reason" => "Won $79.9M competitive NIH SeroNet contract with outlays exceeding base value, indicating program expansion. Contract ends October 2026, creating re-compete catalyst.", "trigger" => "SeroNet contract end date (October 2026); NIH budget allocations for serological research"}

{"entity" => "ADVANCED TECHNOLOGY INTERNATIONAL", "reason" => "Received $1.01B contract (77% of digest value) with no pricing or competition details, creating significant opacity. Contract awarded September 2023, making it vulnerable to CR uncertainty.", "trigger" => "Disclosure of contract details (pricing type, competition type); HHS budget appropriations"}

{"entity" => "BIOQUAL, INC.", "reason" => "$65.5M NIH vaccine research contract with options up to $110.3M through 2027. Option exercises will determine revenue trajectory.", "trigger" => "Option exercise announcements for NIH NIAID contract"}

{"entity" => "Fisher Bioservices Inc.", "reason" => "$62.98M NIH clinical research contract with $18.8M remaining under current funding. Contract runs through June 2027.", "trigger" => "Option exercise announcements; contract end date (June 2027)"}

{"entity" => "HHS BARDA", "reason" => "Awarded two contracts totaling $95.1M for biodefense technologies, signaling increased investment in next-generation platforms.", "trigger" => "BARDA budget allocations; follow-on contract announcements for organ-on-chip and disaster response technologies"}